A. Buck

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

This paper develops a CAR T cell therapy that secretes a CD47 blocker to enhance anti-EGFRvIII efficacy against glioblastoma by modulating the tumor microenvironment.

The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma

This study identifies the Siglec-sialic acid-axis as a target for innate immunotherapy in glioblastoma, showing that blocking Siglec-E enhances phagocytosis and T cell priming, leading to delayed tumor growth and prolonged survival.

B/T cell crosstalk and aberrant inflammatory IgG exacerbate autoimmune intestinal inflammation

This study identifies B cell-driven inflammatory mechanisms, including aberrant IgG production and CD86-mediated T cell activation, as contributors to exacerbated intestinal inflammation in IBD.

The ascorbate-deficient guinea pig model of shigellosis allows the study of the entire Shigella life cycle

This paper develops an ascorbate-deficient guinea pig model to study the full Shigella life cycle and immune responses, showing increased infection severity and prolonged bacterial dissemination.

Analysis of High Molecular Weight RNA-induced silencing complex (HMW-RISC) in CD8+ T cells identifies miR-7 as a modulator of T cell activation

The paper identifies miR-7 as a modulator of T cell activation by showing its enrichment in HMW-RISC and its role in suppressing IL-2 signaling and metabolic processes.

Development of caecaloids to study host-pathogen interactions: new insights into immunoregulatory functions of Trichuris muris extracellular vesicles in the caecum

This paper develops a caecal organoid model to study host-pathogen interactions, revealing immunoregulatory effects of Trichuris muris extracellular vesicles on caecal epithelium.